Reported Q: Q4 2025 Rev YoY: +34.0% EPS YoY: -44,400.0% Move: -5.05%
Tilray Brands Inc
2HQ.DE
€0.680 -5.05%
Exchange XETRA Sector Healthcare Industry Drug Manufacturers Specialty Generic
Q4 2025
Published: Jul 29, 2025

Company Status Snapshot

Fast view of the latest quarter outcome for 2HQ.DE

Reported

Report Date

Jul 29, 2025

Quarter Q4 2025

Revenue

308.10M

YoY: +34.0%

EPS

-17.80

YoY: -44,400.0%

Market Move

-5.05%

Previous quarter: Q3 2025

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

  • Revenue of $308.10M up 34% year-over-year
  • EPS of $-17.80 decreased by 44% from previous year
  • Gross margin of 30.1%
  • Net income of -1.75B
  • "No earnings transcript available in the dataset." -
2HQ.DE
Company 2HQ.DE

Executive Summary

Tilray Brands reported QQ4 2025 results in USD showing healthy top-line growth but severe bottom-line weakness driven by an outsized non-operating charge. Revenue rose 34.0% year over year to $308.1 million, supported by a gross profit of $92.8 million and a gross margin of 30.1%. Despite the top-line improvement, the quarter posted an operating loss of $1.981 billion and an EBITDA loss of $1.844 billion, largely attributable to a substantial 'other expenses' item totaling nearly $2.0 billion. Net income came in at a loss of $1.747 billion, or -$17.80 per share on ~97.8 million weighted-average shares. The contrast between revenue growth and negative profitability signals significant near-term re-leveraging needs and potential one-off charges that obscure underlying operating dynamics.

Key Performance Indicators

Revenue
Increasing
308.10M
QoQ: 14.82% | YoY: 34.03%
Gross Profit
Increasing
92.81M
30.12% margin
QoQ: 23.54% | YoY: 46.62%
Operating Income
Decreasing
-1.98B
QoQ: -80.52% | YoY: -9 519.49%
Net Income
Decreasing
-1.75B
QoQ: -53.17% | YoY: -5 401.36%
EPS
Decreasing
-17.80
QoQ: -41.27% | YoY: -44 400.00%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q2 2026 217.51 -0.41 -26.3% View
Q1 2026 287.78 0.00 +6.7% View
Q4 2025 308.10 -17.80 +34.0% View
Q3 2025 185.78 -0.87 -1.4% View
Q2 2025 210.95 -0.10 +8.9% View